Inhibitors of APOL1 and methods of using same

US12281102B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Leslie Dakin · Waltham, US
• Timothy J. Senter · Arlington, US
• Jingrong Cao · Newton, US
• Jon Come · Cambridge, US
• Francois Denis · Saint Lazare, CA
• Warren Dorsch · Boston, US
• Anne Fortier · Rockville, US
• Martine Hamel · Boston, US
• Elaine B. Krueger · Cambridge, US
• Brian Ledford · Attleboro, US
• Francois Maltais · Somerville, US
• Suganthini S. Nanthakumar · Newton, US
• Olivier Nicolas · Winston-Salem, US
• Camil SAYEGH · Belmont, US
• Tiansheng Wang · Concord, US
• Stephanie Dorich · Rue du Bois des Loges, CA
• Lee Fader · Laval, CA
• Claudio Sturino · Montréal, CA
• Janek Szychowski · Shannon, CA

Key dates

• Filing date: Jun 11, 2021
• Grant date: Apr 22, 2025
• Expiry date: Jun 11, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/05
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of making and using the same, including use in treating APOL1 mediated kidney disease.